# A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

> **NCT06463834** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06463834
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2025-03-19
- **Final completion:** 2028-03-19
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463834, "A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06463834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*